Scope and claims of US Drug Patent 11,649,259 (Form B deoxycytidine + residual solvent controls) and how the patent estate maps to generic and biosimilar entry risk
US 11,649,259 is a crystalline-form and impurity-and-residual-solvent specification patent around Form B deoxycytidine (and combinations with deoxythymidine) plus tightly bounded XRPD peak positions, residual solvent identity and concentration limits (as a fraction of ICH limits), and stability at 25±2°C/60±5% RH. It also contains a fixed-dose product claim, a form-specific process claim to make Form B, and method-of-treatment claims for TK2 deficiency using the specified composition.
What exactly do Claims 1-8 cover for Form B deoxycytidine?
Core claim anchor (Claim 1): a composition comprising
- Form B deoxycytidine with an XRPD fingerprint: peaks at 13.7, 17.2, 18.0, 19.2, 22.8 degrees 2θ (±0.2), and
- At least one residual solvent selected from: methanol, toluene, methylene chloride, ethanol, tert-butylmethyl ether (TBME), acetone, ethyl acetate, n-heptane,
- Residual solvent concentration: < 10% of the ICH concentration limit for each residual solvent, and
- Stability: ≥ 3 months at 25±2°C and 60±5% RH.
Legal and technical significance of the anchor: Claim 1 is not “Form B deoxycytidine alone.” It is Form B defined by XRPD + a residual-solvent regime + shelf-stability. That combination materially tightens the claim’s perimeter for both design-around and infringement proof.
Claim breadth inside Claims 2-6 (polymorph fingerprint refinements and impurity caps)
-
Claim 2 adds optional XRPD peaks (still tied to Form B), requiring additional peaks at: 11.5, 11.8, 20.2, 21.1, 21.4, 21.8 degrees 2θ (±0.2).
- Practical effect: strengthens enforceability against polymorph “near neighbors” that might satisfy only the minimum 5-peak set but miss the added set.
-
Claims 3 and 4 impose specific solvent impurity limits:
- Claim 3: ethyl acetate <100 ppm, n-heptane <100 ppm, ethanol <200 ppm
- Claim 4: ethyl acetate <70 ppm, n-heptane <50 ppm, ethanol <200 ppm
- Practical effect: creates a second infringement handle that can be tested even if residual solvent identity or “% of ICH limits” logic is contested.
-
Claim 5 is a range claim by solvent identity for “at least one residual solvent,” mapping each solvent to ppm sub-ranges:
- Methanol 1–300 ppm
- Toluene 1–89 ppm
- Methylene chloride 1–60 ppm
- Ethanol 1–500 ppm
- TBME 1–500 ppm
- Acetone 1–500 ppm
- Ethyl acetate 1–500 ppm
- n-Heptane 1–500 ppm
This range language is important because it can capture compositions whose residual solvent levels are not cleanly expressed as “<10% ICH” in a practical test report, but do fall within the stated ppm bands.
-
Claim 6: 1,2-dichloroethane is undetectable.
- Practical effect: creates an exclusionary contaminant limitation that can support non-infringement if a competitor’s solvent system introduces measurable 1,2-dichloroethane.
Claim 7-8 (pharmaceutically acceptable carrier; co-formulation ingredient)
- Claim 7: composition further comprises at least one pharmaceutically acceptable carrier.
- Claim 8: composition further comprises deoxythymidine.
Net interpretation: the patent systematically builds from (i) polymorph definition (XRPD), (ii) residual solvent content controls (identity + concentration + “undetectable” exclusions), (iii) stability performance, then expands into (iv) formulation and (v) combination with a second nucleoside (deoxythymidine), which becomes central in the fixed-dose and method claims.
What is protected in the fixed-dose pharmaceutical composition (Claims 9-16)?
Claim 9 is a dedicated combination product claim:
- A fixed-dose pharmaceutical composition that is a powder comprising:
- Form B deoxycytidine
- deoxythymidine
- at least one residual solvent among the same list
- Residual solvent concentration: <10% of ICH limits for each residual solvent
- XRPD: peaks at 13.7, 17.2, 18.0, 19.2, 22.8 degrees 2θ (±0.2)
- Stability: ≥ 3 months at 25±2°C and 60±5% RH
- Weight ratio: deoxycytidine : deoxythymidine = 50:50
Claims 10-14 specify powder excipient architecture:
- Claim 10: carrier comprises glidant + lubricant
- Claim 11: glidant 0.1–10 wt%
- Claim 12: glidant comprises colloidal silicon dioxide
- Claim 13: lubricant 0.1–1 wt%
- Claim 14: lubricant comprises magnesium stearate
Claims 15-16 add composition and packaging:
- Claim 15: deoxycytidine amount 40–50 wt% (consistent with a 50:50 ratio by weight in a two-nucleoside system, subject to carrier/solids)
- Claim 16: powder packaged in a pouch
Practical perimeter: why Claim 9 is commercially significant
- It is not limited to a single route of manufacture.
- It is limited to a defined chemical form (Form B by XRPD) plus defined solvent residue regime plus defined stability plus defined ratio and powder dosage form.
- It also implicitly pressures formulation development: even if a manufacturer achieves the right polymorph, it must also match the residual solvent profile and stability.
What process claim protects Form B manufacture (Claim 17-19)?
Claim 17 is a method for preparing substantially pure Form B deoxycytidine with a specific sequence:
a. Provide crude deoxycytidine mixture of Form A and Form B
b. Contact with ethanol to provide first mixture
c. Distill ethanol from first mixture to provide residue
d. Contact residue with purified water to provide second mixture
e. Heat internal temperature of second mixture to ≥ 40°C
f. Add ethanol, ethyl acetate, and heptane to provide third mixture
g. Cool third mixture to form substantially pure Form B crystals
h. Separate Form B crystals
Claim 18: in step (f), add first portion of ethanol, then add a solution comprising second portion of ethanol + ethyl acetate + n-heptane.
Claim 19: cool third mixture to internal temperature 0–10°C.
Infringement posture for process claims
Because the process is detailed, infringement will typically depend on whether the accused manufacturer follows a substantially identical sequence and conditions. That said:
- If Claim 17 is asserted, the manufacturer will likely argue non-equivalence via different solvent systems, different temperature windows, different water handling, or different crystallization/cooling profiles.
- The fixed-dose and composition claims (Claims 1 and 9) may still catch a product regardless of process, provided the product meets the XRPD + residual solvent + stability criteria.
What “use” is claimed for TK2 deficiency (Claims 20-27)?
Claim 20: a method for treating TK2 deficiency administering a therapeutically effective amount of a composition meeting Claim 1’s restrictions:
- Form B deoxycytidine with the 5-peak XRPD,
- residual solvents in the listed set, each <10% of ICH concentration limit,
- stability ≥ 3 months at 25±2°C/60±5% RH.
Claim 21: further treat with a second composition comprising deoxythymidine.
Claim 22: ratio deoxycytidine:deoxythymidine ~50/50.
Claims 23-24: daily dose range:
- Claim 23 (second composition): 100–1,000 mg/kg/day
- Claim 24 (the first composition): 100–1,000 mg/kg/day
Claim 25: method for treating TK2 deficiency by:
- Dissolving a fixed-dose powder in water to provide a solution
- Powder must include the same residual solvent controls, carriers, and 50/50 ratio
- XRPD and stability criteria remain embedded in the method
- Administering the solution
Claims 26-27: per-component dose amounts in the composition:
- Claim 26: each of Form B deoxycytidine and deoxythymidine 1,000–5,000 mg
- Claim 27: each ~2,000 mg
Litigation-relevant structure
- The method claims are tethered to product features (XRPD + residual solvent + stability). Even a different dosing schedule or administration format will still need to meet those product defining limitations.
- The dissolution-in-water method (Claim 25) is likely to track the real-world drug handling if the product is a reconstitutable powder.
Claim coverage map: how the limitations stack
| Claim group |
Must prove (for infringement) |
Main design-around levers |
| Claims 1-2 |
Form B by XRPD (5 peaks ±0.2); residual solvent identity from list; each residual solvent <10% ICH; shelf stability ≥3 months at specified stress; Claim 2 optionally adds extra XRPD peaks |
Different polymorph (Form A or other form); alter residual solvent identity outside the list; drive residual solvents below detectable or shift to non-listed solvents; show stability mismatch; adjust XRPD peak positions beyond tolerance |
| Claims 3-5 |
Specific ppm thresholds for ethyl acetate, n-heptane, ethanol; or broader ppm ranges by solvent identity |
Adjust residual solvent clean-up profile; avoid producing ethyl acetate/n-heptane/ethanol in the claimed ppm windows; use different residual solvent suite |
| Claim 6 |
1,2-dichloroethane undetectable |
Use a manufacturing route that either doesn’t introduce it or achieves a truly nondetect profile (still must also meet Form B XRPD + other constraints to avoid other claims) |
| Claims 7-8 |
carrier present; optional addition of deoxythymidine |
Harder design-around if combination is intended and ratio is fixed in Claim 9/22 |
| Claim 9 |
all of Claim 1 plus: fixed-dose powder; deoxythymidine included; 50:50 weight ratio; XRPD; stability |
Avoid 50:50, avoid powder, or use a different crystalline form; change residual solvent regime; or change stability profile (commercially harder) |
| Claims 10-16 |
glidant/lubricant composition and amounts; excipient identity (colloidal silicon dioxide; magnesium stearate); pouch packaging |
Substitute excipients or adjust wt% and packaging. Note: Claim 9 remains even if Claims 10-16 are not met, so excipient changes alone may not avoid all infringement |
| Claims 17-19 |
specific manufacturing steps and conditions to create Form B crystals |
Change solvent system order, remove ethanol distillation approach, change temperature/hold or cooling window; avoid substantially pure Form B |
| Claims 20-24 |
TK2 deficiency treatment using Claim 1-defined composition; co-treatment with deoxythymidine; 50/50 ratio; 100-1,000 mg/kg/day windows |
Use a non-Claim 1-defined Form B product (different XRPD profile or residual solvent regime); change ratio; outside dosing window |
| Claims 25-27 |
TK2 method via dissolving fixed-dose powder in water; same embedded product constraints; dose per-component mg amounts |
Change product form or formulation constraints; avoid powder that matches claimed residual solvent/stability; dose outside claimed mg-per-component range |
What is the patent “scope” in plain terms?
The patent reads like a closed loop:
- Crystalline specification (Form B by XRPD peak set, tolerance ±0.2).
- Solvent residue regime (specific residual solvent identities, each below 10% of ICH limits, plus additional ppm-based constraints, plus nondetect 1,2-dichloroethane).
- Shelf-stability (≥3 months at 25±2°C/60±5% RH).
- Product architecture (fixed-dose powder; 50:50 weight ratio; excipient and packaging sub-claims).
- Use (TK2 deficiency treatment, with co-administration and dose ranges; dissolution-in-water method).
From a competitive entry standpoint, infringement risk is driven less by the “therapeutic concept” and more by whether an alternative product can match all embedded physicochemical criteria, including residual solvent and stability.
What patent landscape facts can be concluded from the claim text alone?
Because only claim text and no bibliographic data are provided (filing date, patent term, continuation status, assignee, prosecution history, other related US/WO family members, Orange Book listings, litigation dockets), a complete landscape cannot be generated. This response therefore restricts to scope and claims only, derived directly from US 11,649,259’s asserted claim set.
Key Takeaways
- US 11,649,259 is a Form B deoxycytidine + residual-solvent + stability specification patent, with XRPD-defined polymorph limits as the central technical gate.
- Claim 1 is broad within its defining boundaries: it covers compositions meeting the Form B XRPD pattern, residual solvent identity and concentration regime, and specified stability.
- Claims 9 and 20-27 expand enforceability to the 50:50 fixed-dose powder with deoxythymidine and to TK2 deficiency treatment methods, with embedded product-feature limitations.
- Process Claim 17 protects a specific crystallization workflow to obtain “substantially pure Form B,” but the composition claims are likely the more direct infringement target if an alternative manufacturer supplies a matching Form B product.
- Practical design-around must target at least one of the stacked limitations: XRPD Form B fingerprint, residual solvent identity/concentration (and nondetect 1,2-dichloroethane), stability, 50:50 ratio, or the powder/dosing framework.
FAQs
1) Does US 11,649,259 require the presence of residual solvents, or can they be zero?
The composition claims require “at least one residual solvent” selected from the specified list and set concentration relationships. A formulation with no residual solvent from that set would not meet the claim language as written.
2) If a competitor uses Form B with the correct peaks but different solvent impurities, is it still covered?
Coverage depends on meeting the residual solvent identity and concentration limitations (including additional ppm caps in dependent claims) plus the stability requirement.
3) Are the excipient and pouch limitations (Claims 10-16) necessary to infringe the fixed-dose product claim?
No. Claims 10-16 narrow the carrier and packaging details. Claim 9 stands on its own fixed-dose powder and 50:50 ratio limitations.
4) Can the TK2 deficiency method be avoided by changing dosing amounts while using the same product?
Not if the method is still administered “of a composition” meeting the embedded product constraints. Dose ranges matter only where the method claim includes those ranges (e.g., Claims 23-24, 26-27).
5) What is the strongest factual test for the polymorph element in enforcement?
Powder XRPD measurement showing peaks at the specified angles within the stated tolerance, plus meeting the stability and residual solvent conditions attached to the same product lots.
